12 To 15 Amino Acid Residues In The Peptide Chain Patents (Class 514/21.5)
-
Publication number: 20140179614Abstract: The present invention relates to neural cell survival, differentiation and proliferation promoting peptide fragments derived from metallothioneins (MT), pharmaceutical compositions comprising said peptide fragments and uses thereof for treatment of diseases and conditions where the effects of stimulating neural cell proliferation, differentiation and/or survival, and/or stimulating neural plasticity associated with learning and memory are beneficial for treatment.Type: ApplicationFiled: November 21, 2013Publication date: June 26, 2014Applicant: University of TasmaniaInventors: Vladimir Berezin, Elisabeth Bock, Milena Penkowa
-
Publication number: 20140179607Abstract: The present invention provides peptides that are useful for the treatment of gastrointestinal disorders. The present invention also provides compositions and methods of treating gastrointestinal disorders and pharmaceutical compositions for accomplishing the same. In some embodiments, these pharmaceutical compositions include oral dosage forms.Type: ApplicationFiled: November 9, 2010Publication date: June 26, 2014Applicant: IRONWOOD PHARMACEUTICALS, INCInventors: Mark G. Currie, Angelika Fretzen, Marco Kessler, Daniel P. Zimmer
-
Patent number: 8759300Abstract: Described herein are fragments of fibronectin and vitronectin and variants thereof that have certain activities, including growth factor-binding activity. Also described are fragments of growth factors that bind to fibronectin and inhibit binding of full-length growth factors to fibronectin. Compositions containing such fragments are useful in cosmetic treatments (e.g., the treatment of wrinkles or UV photodamage of skin), and the treatment of wounds and cancer.Type: GrantFiled: June 16, 2008Date of Patent: June 24, 2014Assignee: The Research Foundation for the State University of New YorkInventor: Richard A. Clark
-
Patent number: 8759482Abstract: The invention provides methods for identifying and optimizing peptide substrates for enzymes such as lipoic acid ligase (Lp1A).Type: GrantFiled: October 19, 2010Date of Patent: June 24, 2014Assignee: Massachusetts Institute of TechnologyInventors: Alice Y. Ting, Sujiet Puthenveetil
-
Patent number: 8754046Abstract: The present invention discloses the identification and isolation of novel MHC class II epitopes derived from the cancer antigen, NY ESO-1. The novel MHC class II epitopes from NY-EsO-1 are recognized by CD4+ T lymphocytes in an HLA class II restricted manner, in particular HLA-DR or HLA-DP restricted. The products of the gene are promising candidates for immunotherapeutic strategies for the prevention, treatment and diagnosis of patients with cancer.Type: GrantFiled: September 28, 2009Date of Patent: June 17, 2014Assignee: The United States of America, as represented by the Secretary, Department of Health and Human ServicesInventors: Rong-Fu Wang, Steven A. Rosenberg, Gang Zeng
-
Patent number: 8748575Abstract: Therapeutic peptides having guanylyl cyclase C agonist activity are disclosed. The therapeutic peptides are analogues of the E. coli STa peptide with non-natural amino acid, isosteric or D-amino acid substituents. The therapeutic peptides are useful in the treatment of chronic ideopathic constipation, inflammatory bowel disease, and other diseases. Pharmaceutical compositions comprising the therapeutic peptides are also disclosed.Type: GrantFiled: June 8, 2011Date of Patent: June 10, 2014Assignee: Combimab, Inc.Inventors: Henry Wolfe, Reinhard Ebner
-
Publication number: 20140154291Abstract: Peptides are provided consisting of L- and/or D-amino acids and combinations thereof, which affect myeloid cells by action on the triggering receptors expressed on myeloid cells (TREMs), including TREM-1 and TREM-2. The peptides act on the TREM/DAP-12 signaling complex. Also provided are lipid and sugar conjugated peptides comprising L- or D-amino acids. A method is provided of designing the peptides and lipid- and/or sugar-conjugated peptides comprising L- or D-amino acids. The disclosure relates to the therapy of various myeloid cell-related disease states involving the use of these peptides and compounds. The peptides and compounds are useful in the treatment and/or prevention of a disease or condition where myeloid cells are involved or recruited. The peptides of the present invention also are useful in the production of medical devices comprising peptide matrices (for example, medical implants and implantable devices).Type: ApplicationFiled: July 12, 2013Publication date: June 5, 2014Applicant: SIGNABLOK, INC.Inventor: Alexander B. Sigalov
-
Publication number: 20140155315Abstract: The invention provides a synthetic polypeptide of Formula I? (SEQ ID NO: 1): X1-X2-X3-R—X5-X6-X7-X8-X9-X10-X11-X12-X13??I or an amide, an ester or a salt thereof, wherein X1, X2, X3, X5, X6, X7, X8, X9, X10, X11, X12 and X13 are defined herein. The polypeptides are agonist of the APJ receptor. The invention also relates to a method for manufacturing the polypeptides of the invention, and its therapeutic uses such as treatment or prevention of acute decompensated heart failure (ADHF), chronic heart failure, pulmonary hypertension, atrial fibrillation, Brugada syndrome, ventricular tachycardia, atherosclerosis, hypertension, restenosis, ischemic cardiovascular diseases, cardiomyopathy, cardiac fibrosis, arrhythmia, water retention, diabetes (including gestational diabetes), obesity, peripheral arterial disease, cerebrovascular accidents, transient ischemic attacks, traumatic brain injuries, amyotrophic lateral sclerosis, burn injuries (including sunburn) and preeclampsia.Type: ApplicationFiled: November 18, 2013Publication date: June 5, 2014Applicant: NOVARTIS AGInventors: Frédéric Zecri, Kayo Yasoshima, Philipp Grosche, Jun Yuan, Hongjuan Zhao
-
Patent number: 8741851Abstract: Disclosed herein is a peptide for inhibiting growth of bacterial pathogens in a biological sample, characterized by an amino acid sequence selected from a group consisting of Pro-His-Trp-Trp-Lys-Trp-Ala-Trp-Trp-His-His-Arg-Arg (SEQ ID NO:1), Lys-His-Trp-Trp-Lys-His-Asp-Trp-Trp-Arg-Trp-Arg-Arg (SEQ ID NO:2), and Ile-Leu-Trp-Trp-Leu-Leu-Ala-Trp-Trp-Arg-Trp-Pro-His (SEQ ID NO:3).Type: GrantFiled: June 18, 2013Date of Patent: June 3, 2014Assignee: Universiti MalayaInventors: Shamala Devi Sekaran, Mohd Yasim Md Yusof, Cheng Foh Le
-
Patent number: 8741852Abstract: Disclosed herein is a peptide for inhibiting growth of bacterial pathogens in a biological sample, characterized by an amino acid sequence selected from a group consisting of Gly-Leu-Phe-Asp-Lys-Trp-Ala-Trp-Trp-Arg-Trp-Arg-Arg (SEQ ID NO:1), Gly-Leu-Phe-Asp-Ile-Trp-Ala-Trp-Trp-Arg-Trp-Arg-Arg (SEQ ID NO:2), Gly-Leu-Phe-Asp-Ile-Trp-Lys-Trp-Trp-Arg-Trp-Arg-Arg (SEQ ID No:3), Gly-Leu-Phe-Asp-Ile-Trp-Lys-Lys-Trp-Arg-Trp-Arg-Arg (SEQ ID NO:4), and Gly-Leu-Phe-Asp-Ile-Trp-Lys-Lys-Leu-Arg-Trp-Arg-Arg (SEQ ID NO:5).Type: GrantFiled: June 18, 2013Date of Patent: June 3, 2014Assignee: Universiti MalayaInventors: Shamala Devi Sekaran, Mohd Yasim Md Yusof, Cheng Foh Le
-
Publication number: 20140147414Abstract: Pre-implantation factor (PIF) may be used to treat intracellular damage. Aspects of the invention are directed to a method of treating intracellular damage comprising administering PIF to a subject in need thereof. Some aspects may be directed to methods of increasing cytokine secretion in response to intracellular damage comprising administering PIF to a subject in need thereof. The intracellular damage may be a result of a disease such as Listeria monocytogenes infection, malaria, Lyme disease, cardiovascular disease, duodenal peptic ulcer, atherosclerosis, peritonitis or tuberculosis. In some aspects, a method of treating tuberculosis is disclosed, comprising administering PIF to a subject in need thereof. In some aspects, a method of treating atherosclerosis is disclosed, comprising administering PIF to a subject in need thereof. In some aspects, a method of treating peritonitis is disclosed, comprising administering PIF to a subject in need thereof.Type: ApplicationFiled: March 2, 2012Publication date: May 29, 2014Applicant: BIOINCEPT, LLCInventor: Eytan R. Barnea
-
Publication number: 20140147445Abstract: The CD40L/Mac-1 interaction is selectively targeted by small peptide inhibitors and/or antibodies and such peptides are used for the specific treatment of inflammation and atherogenesis. In particular, pharmaceutical compositions comprising a polypeptide having the amino acid sequence EQLKKSKTL and antibodies specifically binding to an epitope are disclosed.Type: ApplicationFiled: August 17, 2011Publication date: May 29, 2014Applicants: BAKER IDI HEART & DIABETES INSTITUTE HOLDINGS LTD., UNIVERSITATSKLINIKUM FREIBURGInventors: Andreas Zirlik, Dennis Wolf, Karlheinz Peter
-
Patent number: 8735541Abstract: The invention relates to relatively short peptides (termed ?-conotoxins herein), about 10-30 residues in length, which are naturally available in minute amounts in the venom of the cone snails or analogous to the naturally available peptides, and which preferably include two disulfide bonds.Type: GrantFiled: June 6, 2013Date of Patent: May 27, 2014Assignee: The University of Utah Research FoundationInventors: Maren Watkins, Baldomero M. Olivera, David R. Hillyard, J. Michael McIntosh
-
Publication number: 20140140926Abstract: The present invention includes a method of modulating the phagocytic activity of at least one phagocyte in a subject. The present invention also includes a method of providing a composition resistant to phagocytosis to a subject. The present invention further includes a method of treating, ameliorating or preventing an inflammatory disease in a subject.Type: ApplicationFiled: February 7, 2012Publication date: May 22, 2014Applicant: The Trustees of the University of PennsylvaniaInventors: Dennis E. Discher, Pia L. Rodriguez Nunez, Diego A Pantano
-
Publication number: 20140142022Abstract: The invention provides a synthetic polypeptide of Formula I?: or an amide, an ester or a salt thereof, wherein X1, X2, X3, X4, X5, X6, X7, X8, X9, X10, X11, X12 and X13 are defined herein. The polypeptides are agonist of the APJ receptor. The invention also relates to a method for manufacturing the polypeptides of the invention, and its therapeutic uses such as treatment or prevention of acute decompensated heart failure (ADHF), chronic heart failure, pulmonary hypertension, atrial fibrillation, Brugada syndrome, ventricular tachycardia, atherosclerosis, hypertension, restenosis, ischemic cardiovascular diseases, cardiomyopathy, cardiac fibrosis, arrhythmia, water retention, diabetes (including gestational diabetes), obesity, peripheral arterial disease, cerebrovascular accidents, transient ischemic attacks, traumatic brain injuries, amyotrophic lateral sclerosis, burn injuries (including sunburn) and preeclampsia.Type: ApplicationFiled: January 28, 2014Publication date: May 22, 2014Inventors: Frederic ZECRI, Andrei GOLOSOV, Philipp GROSCHE, Kayo YASOSHIMA, Hongjuan ZHAO, Qi-Ying HU, Hidetomo IMASE, David Thomas PARKER
-
Patent number: 8729032Abstract: Provide are a peptide gel with practically sufficient mechanical strength and a self-assembling peptide capable of forming the peptide gel. The self-assembling peptide is formed of the following amino acid sequence: a1b1c1b2a2b3db4a3b5c2b6a4 where: a1 to a4 each represent a basic amino acid residue; b1 to b6 each represent an uncharged polar amino acid residue and/or a hydrophobic amino acid residue, provided that at least five thereof each represent a hydrophobic amino acid residue; c1 and c2 each represent an acidic amino acid residue; and d represents a hydrophobic amino acid residue.Type: GrantFiled: February 12, 2010Date of Patent: May 20, 2014Assignees: Menicon Co., Ltd., National University Corporation Okayama UniversityInventors: Yusuke Nagai, Hidenori Yokoi, Koji Uesugi, Keiji Naruse
-
Patent number: 8729023Abstract: Methods, compositions and articles of manufacture for contributing to the treatment of cancers, including solid tumors, are disclosed. The methods, compositions and articles of manufacture can utilize an endothelin B agonist (ETB) to enhance the delivery and resulting efficacy of a chemotherapeutic agent.Type: GrantFiled: December 11, 2012Date of Patent: May 20, 2014Assignees: Spectrum Pharmaceuticals, Inc., The Board of Trustees of the University of IllinoisInventors: Anil Gulati, Guru Reddy, Luigi Lenaz
-
Publication number: 20140134188Abstract: The invention provides for a method for screening compounds that bind to and modulate the hair-specific G-protein coupled receptor, P2RY5. The invention farther provides for methods for controlling hair growth by administering a P2RY5 modulating compound to a subject.Type: ApplicationFiled: September 30, 2013Publication date: May 15, 2014Applicant: The Trustees of Columbia University in the City of New YorkInventor: Angela M. Christiano
-
Publication number: 20140135276Abstract: The invention provides a peptide or peptidomimetic that is derived from or based upon the amino acid sequence of the C-terminal ?-helix or hypervariable region (HVR) or a Ras protein, a nucleic acid encoding the peptide or peptidomimetic, and methods employing the same.Type: ApplicationFiled: May 25, 2012Publication date: May 15, 2014Applicants: CALIDRIS THERAPEUTICS, LTD., The Board of Trustees of the University of Illinois, The United States of America, as represented by the Secretary, Dep. of Health & Human Services, VANDERBILT UNIVERSITYInventors: Nadya I. Tarasova, Sergey G. Tarasov, Vadim Gaponenko, Joseph Kates, Alla Ivanova, Michael C. Dean
-
Patent number: 8716246Abstract: Azuvirin peptides are small peptide agents useful in delivering functional moieties, such as sensitizers, chemotherapeutic agents and the like to cancer cells expressing ephrin receptors. The peptides are also useful for administration to a patient suffering from a viral infection, or to an individual facing exposure to a viral infection, especially one caused by the Human Immunodeficiency Virus (HIV-1).Type: GrantFiled: January 3, 2012Date of Patent: May 6, 2014Assignee: The Regents of the University of CaliforniaInventors: Piotr P. Ruchala, Robert I. Lehrer
-
Patent number: 8716245Abstract: Provided herein are tissue protective peptides derived from or sharing consensus sequences with portions of cytokine receptor ligands, including Erythropoietin (EPO), that are generally located on or within the region of the cytokine receptor ligand that faces away from a receptor complex while the ligand is bound to the receptor. Also provide herein are fragments, chimeras, as well as peptides designed to mimic the spatial localization of key amino acid residues within the tissue protective receptor ligands, e.g., EPO; methods for treating or preventing a disease or disorder using tissue protective peptides; and methods for enhancing excitable tissue function using tissue protective peptides.Type: GrantFiled: October 20, 2011Date of Patent: May 6, 2014Assignee: Araim Pharmaceuticals, Inc.Inventors: Anthony Cerami, Michael Brines, Thomas Coleman
-
Patent number: 8716247Abstract: The embodiments include methods of treating conditions requiring removal or destruction of cellular elements, such as benign or malignant tumors in humans, using compounds based on small peptides. The method includes, but is not limited to, administering the compounds intramuscularly, orally, intravenously, intrathecally, intratumorally, intranasally, topically, transdermally, etc., either alone or conjugated to a carrier.Type: GrantFiled: November 28, 2011Date of Patent: May 6, 2014Assignee: Nymox CorporationInventors: Paul Averback, Jack Gemmell
-
Publication number: 20140121169Abstract: A method of treatment of inflamed, pre-cancerous or cancerous tissue or polyps in a mammalian subject is disclosed. The treatment involves administration of a composition of at least one peptide agonist of a guanylate cyclase receptor and/or other small molecules that enhance intracellular production of cGMP. The at least one peptide agonist of a guanylate cyclase receptor may be administered either alone or in combination with an inhibitor of cGMP-dependent phosphodiesterase. The inhibitor may be a small molecule, peptide, protein or other compound that inhibits the degradation of cGMP. Without requiring a particular mechanism of action, this treatment may restore a healthy balance between proliferation and apoptosis in the subject's population of epithelial cells, and also suppress carcinogenesis.Type: ApplicationFiled: December 20, 2013Publication date: May 1, 2014Inventors: Kunwar Shailubhai, Gregory Nikiforovich, Gary S. Jacob
-
Publication number: 20140121170Abstract: Novel peptides that inhibit the release of microparticles from cells are disclosed. The peptide contains at least one VGFPV motif at the N-terminal and has a length of 10-100 amino acids. Also disclosed is polynucleotide encoding the peptide, expression vectors carrying the polynucleotide, and methods for treating AIDS and tumors using the novel peptides.Type: ApplicationFiled: August 30, 2013Publication date: May 1, 2014Inventors: Vincent Craig BOND, Michael POWELL, MingBo HUANG, Syed ALI, Andrea D. RAYMOND, Martin Neville SHELTON, Francois Jean VILLINGER
-
Patent number: 8709995Abstract: The invention provides compositions and methods related to human telomerase reverse transcriptase (hTRT), the catalytic protein subunit of human telomerase. The polynucleotides and polypeptides of the invention are useful for diagnosis, prognosis and treatment of human diseases, for changing the proliferative capacity of cells and organisms, and for identification and screening of compounds and treatments useful for treatment of diseases such as cancers.Type: GrantFiled: August 20, 2007Date of Patent: April 29, 2014Assignees: Geron Corporation, The Regents of the University of ColoradoInventors: Thomas R. Cech, Joachim Lingner, Toru M. Nakamura, Karen B. Chapman, Gregg B. Morin, Calvin B. Harley, William H. Andrews
-
Publication number: 20140113875Abstract: The present invention provides herein the design of monodisperse, amphiphilic anticancer drugs—which are now termed “drug amphiphiles” (DAs)—that can spontaneously associate into discrete, stable supramolecular nanostructures with the potential for self-delivery (no additional carriers are needed). The quantitative drug loading in the resulting nanostructures is ensured by the very nature of the molecular design. The DA is a composition comprising: D-L-PEP; wherein D is 1 to 4 hydrophobic drug molecules which can be the same or different; L is 1 to 4 biodegradable linkers which can be the same or different; and PEP is a peptide that can spontaneously associate into discrete, stable supramolecular nanostructures. In an alternate embodiment, the DA composition also comprises a targeting ligand (T). Methods of making DA molecules, as well as their use in treatment of disease are also provided.Type: ApplicationFiled: October 2, 2013Publication date: April 24, 2014Applicant: The Johns Hopkins UniversityInventors: Honggang Cui, Andrew G. Cheetham, Pengcheng Zhang
-
Publication number: 20140113874Abstract: Compounds comprising peptides capable of binding C3 protein and inhibiting complement activation are disclosed. These cyclic compounds are modified to improve stability while maintaining substantially equivalent complement activation-inhibitory activity as compared with currently available compounds. The compounds comprise compstatin analogs in which the disulfide bond between C2 and C12 is modified via a thioether bond to form a cystathionine.Type: ApplicationFiled: September 21, 2011Publication date: April 24, 2014Applicant: THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIAInventors: John D. Lambris, Wilfred A. Van Der Donk
-
Patent number: 8703711Abstract: Methods, uses, agents and compositions useful for the prevention, treatment and/or diagnosis of neuroinflammatory conditions such as multiple sclerosis and spinal cord injury based on the modulation of nerve injury-induced protein-1 (Ninjurin-1) are disclosed.Type: GrantFiled: June 8, 2010Date of Patent: April 22, 2014Assignee: Val-Chum, Limited PartnershipInventors: Alexandre Prat, Simone Terouz, Igal Ifergan, Hania Kebir
-
Patent number: 8703709Abstract: Methods, compositions and articles of manufacture for contributing to the treatment of a solid cancerous tumor are disclosed. The methods, compositions and articles of manufacture can utilize an endothelin B agonist (ETB) to enhance the delivery of a chemotherapeutic agent to a solid tumor in mammals, including humans.Type: GrantFiled: June 7, 2012Date of Patent: April 22, 2014Assignee: The Board of Trustees of the University of IllinoisInventor: Anil Gulati
-
Patent number: 8697651Abstract: The present invention provides a peptide which functions as a mimic peptide of an amyloid ? peptide and is capable of inhibiting the fibrillogenesis of an amyloid ? peptide. The present invention relates to an 8- to 30-amino acid residue peptide comprising an amino acid sequence represented by the following formula (I): X1-Asp-X2-X3-X4-Pro-X5-X6 (SEQ ID NO: 28) (I), wherein X1 represents a branched chain amino acid, and X2, X3, X4, X5, and X6 are the same or different and each represents an ?-amino acid, and to a pharmaceutical composition and an amyloid ? fibrillogenesis inhibitor comprising the peptide.Type: GrantFiled: December 16, 2011Date of Patent: April 15, 2014Assignee: Kagoshima UniversityInventor: Kazuhisa Sugimura
-
Patent number: 8697841Abstract: An isolated peptide including an amino acid sequence of SEQ ID NO: 1 is provided. The disclosure also provides a delivery system comprising a carrier having a surface, a drug or a dye encapsulated in the carrier, and the disclosed peptide (having an amino acid sequence of SEQ ID NO: 1) grafted on the surface of the carrier.Type: GrantFiled: December 28, 2010Date of Patent: April 15, 2014Assignee: Industrial Technology Research InstituteInventors: Maggie J. M. Lu, Hsiang-Fa Liang, Shing-Ming Cheng, Yi-Ju Ko, Li-Wen Chang
-
Patent number: 8697840Abstract: During lung injury, p53 expression increases, inducing plasminogen activator inhibitor-1 (PAI-1) while inhibiting expression of urokinase-type plasminogen activator (uPA) and its receptor (uPAR), resulting in apoptosis of lung epithelial cells (LECs). In the bleomycin lung injury model, p53 and PAI-1 are induced while uPA and uPAR are inhibited. A 20 residue peptide DGIWKASFTTFTVTKYWFYR termed PP-1 (the Cav-1 scaffolding domain) or peptide NYHYLESSMTALYTLGH, termed PP-2, protected LECs from bleomycin-induced apoptosis in vitro and in vivo and prevented subsequent pulmonary fibrosis by attenuating lung epitheilial damage. Pharmaceutical compositions, peptide multimers and deliverable polypeptides comprising the above peptides are dislcosed.Type: GrantFiled: March 5, 2009Date of Patent: April 15, 2014Assignee: Board of Regents, The University of Texas SystemInventors: Sreerama Shetty, Steven Idell
-
Patent number: 8691944Abstract: Described herein are fragments of fibronectin and variants thereof that bind growth factors. Compositions containing such a fragment of fibronectin are therefore useful in sequestering growth factors, and complexes containing both a FN fragment and a bound, active growth factor can be used to deliver growth factors to a patient (e.g., to a wound on the patient's skin).Type: GrantFiled: October 4, 2006Date of Patent: April 8, 2014Assignee: The Research Foundation for the State University of New YorkInventors: Richard A. Clark, Xiang-Dong Ren, Fubao Lin
-
Publication number: 20140088023Abstract: The present invention provides materials and methods useful to treat various sGC?1-expressing cancers. Materials include peptides which interfere with sGC?1's pro-survival functions, thereby resulting in apoptosis of sGC?1-expressing cells. In addition, the present invention provides screening assays, diagnostic assays, methods to prognose, methods to treat, and kits.Type: ApplicationFiled: November 1, 2013Publication date: March 27, 2014Applicant: THE UNIVERSITY OF TOLEDOInventors: Lirim Shemshedini, Shao-Yong Chen, Changmeng Cai, Chen-Lin Hsieh
-
Publication number: 20140087994Abstract: Template-fixed ?-hairpin peptidomimetics of the general formula wherein Z is a template-fixed chain of 12 ?-amino acid residues which, depending on their positions in the chain (counted starting from the N-terminal amino acid) are Gly, or Pro, or of certain types which, as the remaining symbols in the above formula, are defined in the description and the claims, and salts thereof, have the property to selectively inhibit the growth of or to kill microorganisms such as Pseudomonas aeruginosa. They can be used as disinfectants for foodstuffs, cosmetics, medicaments or other nutrient-containing materials, or as medicaments to treat or prevent infections. These ?-hairpin peptidomimetics can be manufactured by processes which are based on a mixed solid- and solution phase synthetic strategy.Type: ApplicationFiled: November 7, 2013Publication date: March 27, 2014Applicants: Universitaet Zuerich, POLYPHOR LTD.Inventors: Steven J. DEMARCO, Wim Vrijbloed, Ricardo Dias, John Anthony Robinson, Nityakalyani Srinivas, Frank Gombert, Daniel Obrecht
-
Publication number: 20140088006Abstract: Stem cells are mobilized from bone marrow by administering an amount of Phe-Pro-His-Phe-Asp-Leu-Ser-His-Gly-Ser-Ala-Gin-Val (SEQ ID NO: 1) effective to mobilize the stem cells. This method is useful for promoting preservation, repair, or regeneration of bodily tissue, or revascularization, in a patient in need of such treatment. Alternatively, the mobilized stem cells can be collected for transplant.Type: ApplicationFiled: May 18, 2012Publication date: March 27, 2014Applicant: Wellstat Therapeutics CorporationInventors: Irena Tsyrlova, Fawn Petty, Reid W. Von Borstel, Julian Reading
-
Patent number: 8680046Abstract: Described herein are compositions and methods for inhibiting HIV integrase activity. Also described are methods of identifying agents that inhibit HIV integrase for use in treating or preventing HIV. Also disclosed are methods of identifying agents that inhibit HIV viral mutants that are resistant to integrase inhibitors.Type: GrantFiled: March 18, 2010Date of Patent: March 25, 2014Assignees: Integratech Proteomics, LLC, The United States of America, as represented by the Secretary of the Department of Health and Human ServicesInventors: Tanya Sandrock, Robert Craigie
-
Patent number: 8673861Abstract: Provided herein are tissue protective peptides derived from or sharing consensus sequences with portions of cytokine receptor ligands, including Erythropoietin (EPO), that are generally located on or within the region of the cytokine receptor ligand that faces away from a receptor complex while the ligand is bound to the receptor. Also provide herein are fragments, chimeras, as well as peptides designed to mimic the spatial localization of key amino acid residues within the tissue protective receptor ligands, e.g., EPO; methods for treating or preventing a disease or disorder using tissue protective peptides; and methods for enhancing excitable tissue function using tissue protective peptides.Type: GrantFiled: April 16, 2012Date of Patent: March 18, 2014Assignee: Araim Pharmaceuticals, Inc.Inventors: Anthony Cerami, Michael Brines, Thomas Coleman
-
Patent number: 8674060Abstract: Loss of Wnt-5a protein expression in breast carcinoma patients is associated with a shorter recurrence-free survival as well as increased motility in mammary cell lines. Based on sequence analysis of Wnt-5a, peptide fragments were identified and investigated for their ability to mimic effects of the Wnt-5a protein on mammary cell adhesion and motility. Two of these peptides significantly increased adhesion and impaired the motility of non-tumorigenic breast cancer cell lines, both low in endogenous Wnt-5a protein expression. To identify the shortest possible peptide that still had an anti-motile effect, sequential deletions of two amino acids from the N-terminal side of the shorter of these two peptides were performed. The effect on tumor cell adhesion was gradually lost, and when only 6 amino acids remained the effect was not detectable. However, formulation of the N-terminal methionine of this hexapeptide restored its effect on adhesion and reduced tumor cell motility.Type: GrantFiled: November 28, 2007Date of Patent: March 18, 2014Assignee: Wntresearch ABInventor: Tommy Andersson
-
Patent number: 8673857Abstract: This invention discloses CN2097-like compositions that facilitate the induction of long-term potentiation (LTP). In one embodiment the method comprises inducing long-term potentiation in a subject by the method of administering a therapeutically effective dose of a CN2097-like compound.Type: GrantFiled: August 27, 2010Date of Patent: March 18, 2014Assignee: Brown UniversityInventors: John Marshall, Andrew Mallon
-
Publication number: 20140065175Abstract: The invention relates to the technological sector of the transport and delivery of molecules into cells, either at cytoplasm or at nucleus or inter-cells (cell to cell transport), using peptides binding proteins from the cell microtubule motor complex, preferably dynein-binding peptides, as carrier/delivery peptides; or functionalized structures, as nanoparticles, linked to said carrier/delivery peptides. This delivery can be useful in many technical fields comprising, among some others: diagnosis, therapy and pharmacology.Type: ApplicationFiled: February 17, 2012Publication date: March 6, 2014Inventors: M. Covadonga Alonso Martí, José Ángel Martínez Escribano
-
Patent number: 8664183Abstract: It is disclosed herein that SPANX-B is uniquely expressed in a number of human tumors and that SPANX-B is an immunogenic antigen that is recognized by human T cells inducing helper CD4+ and cytolytic CD8+ T cell responses. Specific SPANX-B polypeptides and polynucleotides are disclosed that can be used to generate an immune response. In several embodiments, these polypeptides can be used for the treatment of a variety of cancers, including melanoma, colon carcinoma, ovarian cancer, breast cancer, myeloma, lung carcinoma and renal cancer.Type: GrantFiled: February 26, 2010Date of Patent: March 4, 2014Assignee: The United States of America, as represented by the Secretary, Department of Health and Human ServicesInventors: Bira Arya, Vladimir L. Larionov
-
Patent number: 8663651Abstract: The present invention is directed to novel therapeutic uses of T-140 analog peptides and compositions comprising same. Specifically, the invention provides compositions and methods useful for immunomodulation.Type: GrantFiled: December 23, 2007Date of Patent: March 4, 2014Assignee: Biokine Therapeutics Ltd.Inventors: Amnon Peled, Michal Begin, Katia Beider, Michal Abraham
-
Patent number: 8664354Abstract: The invention provides novel guanylate cyclase-C agonist peptides and their use in the treatment of human diseases including gastrointestinal disorders, inflammation or cancer (e.g., a gastrointestinal cancer). The peptides can be administered either alone or in combination with an inhibitor of cGMP-dependent phosphodiesterase. The gastrointestinal disorder may be classified as either irritable bowel syndrome, constipation, or excessive acidity etc. The gastrointestinal disease may be classified as either inflammatory bowel disease or other GI condition including Crohn's disease and ulcerative colitis, and cancer.Type: GrantFiled: July 31, 2013Date of Patent: March 4, 2014Assignee: Synergy Pharmaceuticals Inc.Inventor: Kunwar Shailubhai
-
Patent number: 8663617Abstract: The current invention relates to methods and compositions for the treatment of wounds in a mammalian subject. Particularly, the invention relates to novel polypeptides and encoding nucleic acids that stimulate keratinocyte and endothelial cell motility and/or proliferation.Type: GrantFiled: October 16, 2012Date of Patent: March 4, 2014Assignee: Tufts UniversityInventor: Ira M Herman
-
Patent number: 8658599Abstract: A method to inhibit the formation of skin tumors at early stages and their subsequent progression to carcinoma in a mammal is described, the method including the topical application to the mammal's skin of a composition that includes a therapeutically effective amount of disitertide, together with pharmaceutically acceptable carriers or diluents.Type: GrantFiled: March 4, 2010Date of Patent: February 25, 2014Assignee: Digna Biotech, S.L.Inventors: Raul Insa Boronat, Miguel Quintanilla Avila, Javier Dotor De Las Herrerías
-
Patent number: 8658604Abstract: Template-fixed ?-hairpin peptidomimetics of the general formulae wherein Z is a chain of 11 ?-amino acid residues which, depending on their positions in the chain (counted starting from the N-terminal amino acid) are Gly, or Pro, or Pro(4NHCOPhe), or of certain types which, as the remaining symbols in the above formula, are defined in the description and the claims, and salts thereof, have the property to inhibit proteases, in particular serine proteases, especially Cathepsin G or Elastase or Tryptase. These ?-hairpin peptidomimetics can be manufactured by processes which are based on a mixed solid- and solution phase synthetic strategy.Type: GrantFiled: February 17, 2005Date of Patent: February 25, 2014Assignees: Polyphor Ltd, Universitat ZurichInventors: Steven J. DeMarco, Kerstin Moehle, Heiko Henze, Odile Sellier, Françoise Jung, Frank Gombert, Daniel Obrecht, Christian Ludin
-
Publication number: 20140051647Abstract: This invention provides a TNFR2 expression-inducing composition including as an active ingredient a peptide having TNFR2 expression-inducing activity, and a method for producing cells that express TNFR2 selectively by use of the composition. The cell production method provided by this invention includes: culturing at least one species of cells capable of expressing TNF receptor 2, and supplying the cells with a synthetic peptide consisting of a nuclear localization signal sequence (NLS) or a nucleolar localization signal sequence (NoLS) to enhance TNFR2 expression in the cells.Type: ApplicationFiled: April 17, 2012Publication date: February 20, 2014Applicant: TOAGOSEI CO. LTD.Inventors: Nahoko Kobayashi, Tetsuhiko Yoshida, Mikio Niwa
-
Publication number: 20140045759Abstract: Compositions that include isolated peptides that inhibit TLR-4 signaling pathways and inflammation are disclosed. Methods of producing and using the compositions to inhibit TLR-4 signaling and/or inflammation are also disclosed herein.Type: ApplicationFiled: August 30, 2013Publication date: February 13, 2014Applicant: The Board of Regents of the University of OklahomaInventor: Shanjana Awasthi
-
Publication number: 20140045769Abstract: The present invention relates to peptides having one or more stable, internally-constrained HBS ?-helices, where the peptide is capable of interacting with Ras and related proteins.Type: ApplicationFiled: March 2, 2012Publication date: February 13, 2014Applicant: NEW YORK UNIVERSITYInventors: Paramjit Arora, Dafna Bar-Sagi, Anupam Patgiri, Kamlesh Yadav